Interaction of rabeprazole with phenytoin sodium: a prospective study

Pramod Mohanrao Kshirsagar; Kantilal C. Chandaliya; Mirza Shiraz Baig

doi:10.18203/2320-6012.ijrms20242214

Authors

Pramod Mohanrao Kshirsagar Department of Pharmacology, Government Medical College, Sambhajinagar (Aurangabad), Maharashtra, India
Kantilal C. Chandaliya Department of Pharmacology, Government Medical College, Nanded, Maharashtra, India
Mirza Shiraz Baig Department of Pharmacology, Government Medical College, Sambhajinagar (Aurangabad), Maharashtra, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20242214

Keywords:

HPLC, Pharmacokinetics, Phenytoin, Rabeprazole

Abstract

Background: Phenytoin Sodium, a commonly prescribed anti-epileptic, with narrow therapeutic index, may interact with Rabeprazole, a commonly used Proton Pump Inhibitor (PPI), as both are metabolized by CYP2C19, potentially impacting bioavailability, therapeutic outcomes, and patient safety.

Methods: A total of 52 epileptic patients, previously stabilized on phenytoin, have now been prescribed Tab Rabeprazole for a minimum of 30 days and were included in the study after meeting the other inclusion criteria. On day-0, a blood sample was collected from these patients, and plasma phenytoin level was determined using High-Performance Liquid Chromatography (HPLC). Additionally, clinical evaluations and assessments of other routine laboratory parameters were conducted. The Follow-up evaluations was done on day-15 and day-30, replicating the procedures employed on day-0, including both clinical, laboratory assessments and plasma phenytoin level measurement using HPLC. All data was recorded in the case report form, and statistical analysis was done.

Results: The mean Phenytoin level exhibited a non-significant increase, rising from 15.49 μg/ml on day-0 to 15.57 μg/ml on day-15 and further to 15.75 μg/ml on day -0. Notably, there was no change in epilepsy outcomes concerning both seizure frequency and adverse effects. Additionally, there were no statistically significant changes observed in epilepsy control, SBP, DBP, and routine laboratory parameters, including haemoglobin, TLC, DLC, platelet count, serum albumin, serum globulin, serum bilirubin, SGOT, SGPT, serum urea, serum creatinine, and BSL (random).

Conclusions: The co-administration of rabeprazole with Phenytoin resulted in a non-significant increase in Phenytoin levels, while maintaining stable control of epilepsy.

Metrics

Metrics Loading ...

References

Stafstrom CE, Carmant L. Seizures and Epilepsy: An Overview for Neuroscientists. Cold Spring Harbor Perspectives in Medicine. 2015;5(6):22426.

Gururaj G, Satishchandra P, Amudhan S. Epilepsy in India I: Epidemiology and public health. Ann Indian Acad Neurol. 2015;18(3):263.

Vajda FJE, Eadie MJ. The clinical pharmacology of traditional antiepileptic drugs. Epileptic Disorders. 2014;16(4):395–408.

Dahiya K, Bansal P, Ghalaut VS, Dhankhar R, Ghalaut P. Therapeutic drug monitoring for antiepileptic drugs using HPLC: An experience at a tertiary care hospital in India. Neurology Asia. 2010;5.

Garg SK, Gupta MC, Handu SS, Bhargava VK. Therapeutic drug monitoring of antiepileptic drugs-a preliminary experience. 2098;7(171):94-7.

Yu L, Jiang W, Zhang X, Lionberger R, Makhlouf F, Schuirmann D. Novel bioequivalence approach for narrow therapeutic index drugs. Clin Pharmacol Ther. 2015;97(3):286–91.

Vachhani R, Olds G, Velanovich V. Esomeprazole: a proton pump inhibitor. Expert Review of Gastroenterology and Hepatology. 2009;3(1):15–27.

Pallotta S, Pace F, Marelli S. Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease. Expert Review of Gastroenterology and Hepatology. 2008;2(4):509–22.

Carswell CI, Goa KL. Rabeprazole: An Update of its Use in Acid-Related Disorders. Drugs. 2001;61(15):2327–56.

Jarrar YB, Lee SJ. Molecular functionality of CYP2C9 polymorphisms and their influence on drug therapy. Drug Metabolism and Drug Interactions. 2020;29:4.

Franco V, Perucca E. CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects. Expert Opinion on Drug Metabolism and Toxicology. 2015;11(8):1269–79.

Chiba K, Shimizu K, Kato M, Nishibayashi T, Terada K, Izumo N, et al. Prediction of Inter-individual Variability in the Pharmacokinetics of CYP2C19 Substrates in Humans. Drug Metabolism and Pharmacokinetics. 2014;29(5):379–86.

Medhi B, Prakash A, Joshi R, Byrav DSP. Effect of esomeprazole on pharmacokinetics of phenytoin in rabbits. Indian J Physiol Pharmacol. 2012;56(4):382–7.

Humphries TJ, Spera AC, Laurent AL, Spanyers SA. Rabeprazole sodium (E3810), 20 mg daily does not affect the pharmacokinetics of phenytoin sodium in normal volunteers. Am J Gastroenterol. 1996;91:1914.

Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet. 1996;31(1):9–28.

Zvyaga T, Chang SY, Chen C, Yang Z, Vuppugalla R, Hurley J, et al. Evaluation of Six Proton Pump Inhibitors as Inhibitors of Various Human Cytochromes P450: Focus on Cytochrome P450 2C19. Drug Metab Dispos. 2012;40(9):1698–711.

VandenBranden M, Ring BJ, Binkley SN, Wrighton SA. Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. Pharmacogenetics. 1996;6(1):81–91.

Li XQ, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32(8):821–7.

Liver enzyme induction and inhibition: implications for anaesthesia - Sweeney - 2006 - Anaesthesia - Wiley Online Library. 2021:16.

Buchthal F, Svensmark O, Schiller PJ. Clinical and Electroencephalographic Correlations with Serum Levels of Diphenylhydantoin. AMA Arch Neurol. 1960;2(6):624–30.

Reynolds EH. Serum levels of anticonvulsant drugs interpretation and clinical value. Pharmacology and Therapeutics. 1980;8(2):217–35.